5.40
-0.0443(-0.81%)
Currency In USD
| Previous Close | 5.44 |
| Open | 5.22 |
| Day High | 5.44 |
| Day Low | 5.22 |
| 52-Week High | 19.2 |
| 52-Week Low | 2.69 |
| Volume | 2,419 |
| Average Volume | 119,778 |
| Market Cap | 14.44M |
| PE | -0.21 |
| EPS | -25.97 |
| Moving Average 50 Days | 5.13 |
| Moving Average 200 Days | 7.26 |
| Change | -0.04 |
If you invested $1000 in NextCure, Inc. (NXTC) since IPO date, it would be worth $22.6 as of September 13, 2025 at a share price of $5.396. Whereas If you bought $1000 worth of NextCure, Inc. (NXTC) shares 5 years ago, it would be worth $48.66 as of September 13, 2025 at a share price of $5.396.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Sep 04, 2025 11:00 AM GMT
BELTSVILLE, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta
GlobeNewswire Inc.
Jul 24, 2025 8:05 PM GMT
BELTSVILLE, Md., July 24, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
GlobeNewswire Inc.
Jun 16, 2025 11:05 AM GMT
NextCure gains global rights to SIM0505 excluding greater China, where Simcere Zaiming will retain rightsPhase 1 clinical trial ongoing for SIM0505 in China; U.S. Phase 1 clinical trial is expected to begin in the third quarter of 2025Initial Phase 1